Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways.
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways.
复制标题
DOI:
10.1016/j.isci.2022.104914
复制
发表时间:
2022-09-16
期刊:
影响因子:
5.8
通讯作者:
Jardine, Joseph G.
中科院分区:
文献类型:
--
作者:
Zhao, Fangzhu;Keating, Celina;Ozorowski, Gabriel;Shaabani, Namir;Francino-Urdaniz, Irene M.;Barman, Shawn;Limbo, Oliver;Burns, Alison;Zhou, Panpan;Ricciardi, Michael J.;Woehl, Jordan;Tran, Quoc;Turner, Hannah L.;Peng, Linghang;Huang, Deli;Nemazee, David;Andrabi, Raiees;Sok, Devin;Teijaro, John R.;Whitehead, Timothy A.;Ward, Andrew B.;Burton, Dennis R.;Jardine, Joseph G.
The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and prevent viral neutralization. Here, we used a directed evolution-based approach to engineer three neutralizing antibodies for enhanced binding to S protein. The engineered antibodies showed increased in vitro functional activity in terms of neutralization potency and/or breadth of neutralization against viral variants. Deep mutational scanning revealed that higher binding affinity reduces the total number of viral escape mutations. Studies in the Syrian hamster model showed two examples where the affinity-matured antibody provided superior protection compared to the parental antibody. These data suggest that monoclonal antibodies for antiviral indications would benefit from affinity maturation to reduce viral escape pathways and appropriate affinity maturation in vaccine immunization could help resist viral variation. Cryo-EM analysis of Class 2 and Class 3 SARS-CoV-2 neutralizing monoclonal antibodies Engineered antibodies with higher affinity neutralize emerging SARS-CoV-2 variants The higher affinity antibodies reduce the pathways for viral escape Engineered antibodies improve protection in hamster model Immunology; Virology; Structural biology.
登录
查看更多内容
影响因子:
48
作者:
Barad BA;Echols N;Wang RY;Cheng Y;DiMaio F;Adams PD;Fraser JS
通讯作者:
Fraser JS
影响因子:
64.8
作者:
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者:
Bjorkman PJ
影响因子:
64.8
作者:
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者:
Nussenzweig MC
影响因子:
8.8
作者:
Francino-Urdaniz IM;Steiner PJ;Kirby MB;Zhao F;Haas CM;Barman S;Rhodes ER;Leonard AC;Peng L;Sprenger KG;Jardine JG;Whitehead TA
通讯作者:
Whitehead TA
影响因子:
56.9
作者:
Hsieh, Ching-Lin;Goldsmith, Jory A.;McLellan, Jason S.
通讯作者:
McLellan, Jason S.